Also agree with your sentiments john12, however the short / med term value in this stock is clearly FDA approval (which I think is likely) and not commercialisation of ilumen. In the longer term (say 12-24m) post FDA there will be some upside to revenue growth but SP is all about FDA!!
Ann: FDA Strategy and Regulatory Update, page-251
-
- There are more pages in this discussion • 442 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TRI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.24M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.5¢ | $16.53K | 661.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 2314300 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 190000 | 1 |
View Market Depth
| Last trade - 15.42pm 20/06/2024 (20 minute delay) ? |
| TRI (ASX) Chart |